Wechselwirkungen · Zonegran
Zonegran 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 51
HOS-113447 · Präparat HOS-093917
- Enzyme induction: Exposure to zonisamide is lower in epileptic patients receiving CYP3A4-inducing agents such as phenytoin, carbamazepine, and phenobarbitone. These effects are unlikely to be of clinical significance when Zonegran is added to existing therapy; however, changes in zonisamide concentrations may occur if concomitant CYP3A4-inducing anti-epileptic or other medicinal products are withdrawn, dose adjusted or introduced, an adjustment of the Zonegran dose may be required. Rifampicin is a potent CYP3A4 inducer. If co-administration is necessary, the patient should be closely monitored and the dose of Zonegran and other CYP3A4 substrates adjusted as needed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-22T12:25:00Z · SHA-256 5bc336efc4e06d1dd2b625b17230707f7f9bccaf0010aa953672e95dd43431c7 · Passage bac160266b0ad6fcd464bec2e23ceac1be6f7e92567f12a694a27b1c11e49399 · Zeichen 2637–3358 im Abschnitt